MedTrace Logo

Identifying Brain and Genetic Markers of Sertraline Treatment Response in People With Social Anxiety Disorder

NCT00872131 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2011-11-23

No results posted yet for this study

Summary

This study will attempt to identify gene and brain activity markers that predict whether people with social anxiety disorder will respond to selective serotonin reuptake inhibitor medications.

Conditions

  • Anxiety Disorders

Interventions

DRUG

Sertraline

Oral sertraline will begin at 50 mg per day, then increase to 75 mg per day on Day 8, then increase to 100 mg per day on Day 15. The dose may be increased to 150 mg per day on Week 8, based on clinical response and medication toleration.

Sponsors & Collaborators

Principal Investigators

  • K. Luan Phan, MD · University of Michigan

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2011-05-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00872131 on ClinicalTrials.gov